Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ANTX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Eric Easom | 2.41M | 6.2% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Matthew D. Perry | 3.80M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Coastlands Capital LLC | 3.80M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Coastlands Capital GP LLC | 3.80M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Coastlands Capital Partners LP | 3.80M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Coastlands Capital LP | 3.80M | 10.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Almitas Capital LLC | 1.48M | 4.1% | SCHEDULE 13G/A ↗ |
| Mar 16, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Michael Kramarz | 3.70M | 9.9% | SCHEDULE 13G ↗ |
| Mar 16, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Robert Egen Atkinson | 3.70M | 9.9% | SCHEDULE 13G ↗ |
| Mar 16, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Commodore Capital Master LP | 3.70M | 9.9% | SCHEDULE 13G ↗ |
| Mar 16, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Commodore Capital LP | 3.70M | 9.9% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Vivo Opportunity Cayman, LLC | 289,294 | 0.8% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Vivo Opportunity Cayman Fund, L.P. | 289,294 | 0.8% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Vivo Opportunity, LLC | 2.86M | 8.0% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Vivo Opportunity Fund Holdings, L.P. | 2.86M | 8.0% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Israel A. Englander | 2.24M | 6.3% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Millennium Group Management LLC | 2.24M | 6.3% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Millennium Management LLC | 2.24M | 6.3% | SCHEDULE 13G ↗ |
| Mar 13, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Integrated Core Strategies (US) LLC | 2.14M | 6.0% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Almitas Capital LLC | 2.98M | 5.4% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Eric Easom | 2.23M | 7.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Almitas Capital LLC | 1.43M | 5.2% | SCHEDULE 13G ↗ |
| Jun 18, 2025 | SCHEDULE 13D/A (amended) | ANTX AN2 Therapeutics, Inc. | BML Investment Partners, L.P. | 427,432 | 1.4% | SCHEDULE 13D/A ↗ |
| Jun 4, 2025 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Matthew D. Perry | 2.82M | 9.3% | SCHEDULE 13G ↗ |
| Jun 4, 2025 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Coastlands Capital LLC | 2.82M | 9.3% | SCHEDULE 13G ↗ |
| Jun 4, 2025 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Coastlands Capital GP LLC | 2.82M | 9.3% | SCHEDULE 13G ↗ |
| Jun 4, 2025 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Coastlands Capital Partners LP | 2.82M | 9.3% | SCHEDULE 13G ↗ |
| Jun 4, 2025 | SCHEDULE 13G | ANTX AN2 Therapeutics, Inc. | Coastlands Capital LP | 2.82M | 9.3% | SCHEDULE 13G ↗ |
| May 30, 2025 | SCHEDULE 13D/A (amended) | ANTX AN2 Therapeutics, Inc. | BML Investment Partners, L.P. | 3.22M | 10.7% | SCHEDULE 13D/A ↗ |
| May 7, 2025 | SCHEDULE 13D | ANTX AN2 Therapeutics, Inc. | BML Investment Partners, L.P. | 5.75M | 19.1% | SCHEDULE 13D ↗ |
| Feb 28, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Adjuvant Capital Management, L.L.C. | 2.37M | 7.9% | SCHEDULE 13G/A ↗ |
| Feb 28, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Adjuvant Capital GP, L.P. | 2.37M | 7.9% | SCHEDULE 13G/A ↗ |
| Feb 28, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund DE, L.P. | 377,542 | 1.3% | SCHEDULE 13G/A ↗ |
| Feb 28, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 2.00M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Rajeev Shah | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Peter Kolchinsky | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | RA Capital Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Daniel Estes | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | James Brush | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Albert Cha | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Patrick J. Heron | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | James N. Topper | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Fhmls Xi, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Fhmls Xi, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Frazier Life Sciences XI, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Fhmls X, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Fhmls X, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Frazier Life Sciences X, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | ANTX AN2 Therapeutics, Inc. | Fhmlsp, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances